Program
HS-10504
A development code. Also written as “[¹⁴C]HS-10504” and “HS-10504; midazolam”.
In Hansoh Pharmaceutical Group's pipeline, 4th-gen EGFR
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.
Furthest: phase 3, since Aug 4, 20267 company-led studies, 7 open or runningNext primary completion: Nov 19, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 77 open or running | phase 3since Aug 4, 2026 | Jun 5, 2024 | Nov 19, 2026phase 1 · NCT07685041 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10504 (4th-gen EGFR)
, phase 3, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06461156 · 230 planned · China
- Jun 1, 2026Phase 1 study in NSCLCNCT07685041 · 24 planned
- Jul 20, 20263 phase 1 studiesNCT07770217, NCT07764705, NCT07764692
- Aug 4, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07754123 · 206 planned · China
- Sep 11, 2026Phase 1 study in To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic FunctionNCT07836504 · 32 planned
Ahead
- Nov 19, 2026Primary completion: phase 1 study in NSCLCNCT07685041
- Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06461156
- Mar 1, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07764692
- Sep 25, 2027Primary completion: phase 1 study in To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic FunctionNCT07836504
TargetBeta
“4th-gen EGFR”the company's pipeline, read by Claude · source
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07836504To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function | 1 | Not yet recruiting | Sep 25, 2027 | 32 |
| NCT07754123Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Aug 31, 2028 | 206 |
| NCT07770217Healthy Participants | 1 | Not yet recruiting | Sep 10, 2026 | 18 |
| NCT07764705Healthy Subjects | 1 | Not yet recruiting | Sep 30, 2026 | 6 |
| NCT07764692Healthy Participants | 1 | Not yet recruiting | Mar 1, 2027 | 8 |
| NCT07685041NSCLC | 1 | Not yet recruiting | Nov 19, 2026 | 24 |
| NCT06461156Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Dec 31, 2026 | 230 |
How it is read
Names in the registry
- “HS-10504”, 5 entries
- “[¹⁴C]HS-10504”, 1 entry
- “HS-10504; midazolam”, 1 entry
Codes read as this program: HS10504.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.